戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 tis B, as therapy in 5 patients with chronic hepatitis D.
2 levels were reduced in patients with chronic hepatitis D.
3  virologic response in patients with chronic hepatitis D.
4 alternative treatment options are needed for hepatitis D.
5 ant women, in children, and in patients with hepatitis D and C virus coinfection.
6 evalence of HIV, alcohol, smoking, diabetes, hepatitis D and E, and autoimmune hepatitis serological
7 evalence of HIV, alcohol, smoking, diabetes, hepatitis D and E, and autoimmune hepatitis serological
8 y was shown to be effective in patients with hepatitis D and ribavirin provides no additional benefit
9 hepatitis B e antigen [HBeAg] negative, anti-hepatitis D antigen [HDAg] positive, and HDV RNA positiv
10 s of diversifying selective pressures on the hepatitis D antigen gene (HDAg).
11  would be the preferred endpoint for chronic hepatitis D, but HDV RNA < LLOQ 24 weeks off-treatment i
12                                      Chronic hepatitis D causes more rapidly progressive liver diseas
13 stigate the efficacy of entecavir in chronic hepatitis D (CHD).
14 d treatment option for patients with chronic hepatitis D (CHD).
15 on outlives in aging cirrhotics who acquired hepatitis D decades ago.
16 alpha, the only treatment option for chronic hepatitis D for many years, has limited efficacy.
17 proximately 20% to 50% of people infected by hepatitis D have been diagnosed due to lack of awareness
18 ximately 30% to 70% of patients with chronic hepatitis D have cirrhosis at diagnosis and more than 50
19 dies to hepatitis B e antigen, antibodies to hepatitis D, hepatitis B virus (HBV) DNA for hepatitis B
20                     The combined hepatitis B-hepatitis D (HEPB-HEPD) disease is the severest form of
21 of liver explant tissue from 5 patients with hepatitis D-induced cirrhosis, using a deep-sequencing s
22                                      Chronic hepatitis D infection results in the most severe form of
23 gests that acute HCV infection, unrecognized hepatitis D infection, and hepatitis E may all represent
24                                              Hepatitis D is caused by the hepatitis D virus (HDV); it
25                                      Chronic hepatitis D is the most debilitating form of viral hepat
26                                              Hepatitis D is the most severe form of chronic viral hep
27 rrhosis, and no patients in either group had hepatitis D or E viraemia.
28 osis and their event rates in this cohort of hepatitis D patients did not differ from a matched HBV m
29 restimated in hepatitis D virus RNA negative hepatitis D patients with advanced liver fibrosis.
30     Severe clinical events occurred in 11/49 hepatitis D patients, including HCC (8/49), death (8/49)
31 ctive factor for overall clinical outcome of hepatitis D patients.
32 s and ranges from highly site selective with hepatitis D RNA and glutamate receptor precursor messeng
33 ring acute flares of disease, and with acute hepatitis D superinfection.
34      Coinfection with HBV and HDV results in hepatitis D, the most severe form of chronic viral hepat
35 to conduct a national study of patients with hepatitis D to understand the natural history and outcom
36 TA1), the latter of which is associated with hepatitis D viral infection.
37                                          The hepatitis D virion is composed of a coat of HBV envelope
38                                              Hepatitis D virus (also known as hepatitis delta virus)
39                             Coinfection with hepatitis D virus (HDV) accelerates the progression of l
40  activity of vanitaracin A was observed with hepatitis D virus (HDV) but not hepatitis C virus.
41                                           No hepatitis D virus (HDV) cases were detected.
42                                          The hepatitis D virus (HDV) causes the most severe form of c
43  The primary endpoint for phase 3 trials for hepatitis D virus (HDV) co-infection should be undetecta
44 ron alfa-2a in patients with chronic HBV and hepatitis D virus (HDV) co-infection.
45 eficiency virus (HIV), hepatitis C virus, or hepatitis D virus (HDV) coinfection were excluded.
46 cularly in patients transplanted for HBV and hepatitis D virus (HDV) coinfection, remains controversi
47 s with the human hepatitis B virus (HBV) and hepatitis D virus (HDV) depend on species-specific host
48                                              Hepatitis D virus (HDV) infection affects 15-20 million
49 icacy and safety in the treatment of chronic hepatitis D virus (HDV) infection are unknown.
50  appears to be an autonomous, or "isolated," hepatitis D virus (HDV) infection following the transpla
51                             The emergence of hepatitis D virus (HDV) infection in the era of widespre
52                                      Chronic hepatitis D virus (HDV) infection increases the risk of
53                                              Hepatitis D virus (HDV) infection occurs in association
54      The role of hepatitis B virus (HBV) and hepatitis D virus (HDV) infection was investigated as th
55 and treatment of hepatitis B virus (HBV) and hepatitis D virus (HDV) infections, we still do not comp
56          Knowledge about the epidemiology of hepatitis D virus (HDV) is essential for effective scree
57                          Superinfection with hepatitis D virus (HDV) may increase the risk for hepati
58 en (HBsAg) that is required for synthesis of hepatitis D virus (HDV) particles and the abundant subvi
59                                              Hepatitis D virus (HDV) particles pseudotyped with HBV a
60                                              Hepatitis D virus (HDV) requires hepatitis B surface ant
61                                              Hepatitis D virus (HDV) requires hepatitis B surface ant
62 imary end point was an undetectable level of hepatitis D virus (HDV) RNA at 24 weeks after the end of
63 vir disoproxil fumarate (TDF) would increase hepatitis D virus (HDV) RNA suppression is unknown.
64 h or without achieving an undetectable serum hepatitis D virus (HDV) RNA, as a marker of virologic re
65                                              Hepatitis D virus (HDV) superinfection in patients with
66                                              Hepatitis D virus (HDV) superinfection of patients with
67             As previously shown by using the hepatitis D virus (HDV) system, recombinant HBV-HDV part
68                                              Hepatitis D virus (HDV) was first described in 1977 and
69 ch inhibited the process of entry of HBV and hepatitis D virus (HDV).
70                 Hepatitis D is caused by the hepatitis D virus (HDV); it is the most severe form of v
71      We aimed to establish the prevalence of hepatitis D virus among HBsAg-positive populations in su
72  persons co-infected with hepatitis C virus, hepatitis D virus and/or human immunodeficiency viruses
73 odies, and 22 (10%) of 223 were positive for hepatitis D virus antibodies.
74 n binding and in vitro infection assays with hepatitis D virus as a surrogate for HBV, we established
75 tions if HBV recurrence occurs (i.e., HIV or hepatitis D virus coinfection, preexisting drug resistan
76                      The odds ratio for anti-hepatitis D virus detection among HBsAg-positive patient
77 TION: Findings suggest localised clusters of hepatitis D virus endemicity across sub-Saharan Africa.
78 y was confirmed by an HBV reporter virus and hepatitis D virus infection system.
79 a, where HBsAg prevalence is higher than 8%, hepatitis D virus might represent an important additive
80                                              Hepatitis D virus particles pseudotyped with surface pro
81        We systematically reviewed studies of hepatitis D virus prevalence among HBsAg-positive popula
82 y, only eight of which included detection of hepatitis D virus RNA among anti-hepatitis D virus serop
83 cular, HCC risk may not be underestimated in hepatitis D virus RNA negative hepatitis D patients with
84 etection of hepatitis D virus RNA among anti-hepatitis D virus seropositive participants.
85 ects model to calculate a pooled estimate of hepatitis D virus seroprevalence.
86 dies should aim to define the reliability of hepatitis D virus testing methods, identify risk factors
87 In west Africa, the pooled seroprevalence of hepatitis D virus was 7.33% (95% CI 3.55-12.20) in gener
88  expression was observed in cirrhosis due to hepatitis D virus, followed by hepatitis C virus, hepati
89 nfect the salivary gland: hepatitis C virus, hepatitis D virus, severe acute respiratory syndrome cor
90 ) positive, human immunodeficiency virus and hepatitis D virus-negative patients with pretransplant H
91 , the countries therein, and permutations of hepatitis D virus.
92 HBV genotypes and co-infections with HIV and hepatitis D virus.
93 erived primary hepatocytes were resistant to hepatitis D viruses pseudotyped with CSHBV surface prote
94     The receptor that allows hepatitis B and hepatitis D viruses to enter human liver cells has been
95 ongoing phase 3 trial, patients with chronic hepatitis D, with or without compensated cirrhosis, were